BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In fact, the targeting of autophagy with inhibitors in combination with conventional therapy has been suggested in the CML treatment, also to counteract the BCR-ABL-independent mechanism of resistance (Mitchell et al., 2018).